Skip to main content
Erschienen in: PharmacoEconomics 9/2013

01.09.2013 | Original Research Article

Smoking Cessation Treatment and Outcomes Patterns Simulation: A New Framework for Evaluating the Potential Health and Economic Impact of Smoking Cessation Interventions

verfasst von: Denis Getsios, Jenő P. Marton, Nikhil Revankar, Alexandra J. Ward, Richard J. Willke, Dale Rublee, K. Jack Ishak, James G. Xenakis

Erschienen in: PharmacoEconomics | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Most existing models of smoking cessation treatments have considered a single quit attempt when modelling long-term outcomes.

Objective

To develop a model to simulate smokers over their lifetimes accounting for multiple quit attempts and relapses which will allow for prediction of the long-term health and economic impact of smoking cessation strategies.

Methods

A discrete event simulation (DES) that models individuals’ life course of smoking behaviours, attempts to quit, and the cumulative impact on health and economic outcomes was developed. Each individual is assigned one of the available strategies used to support each quit attempt; the outcome of each attempt, time to relapses if abstinence is achieved, and time between quit attempts is tracked. Based on each individual’s smoking or abstinence patterns, the risk of developing diseases associated with smoking (chronic obstructive pulmonary disease, lung cancer, myocardial infarction and stroke) is determined and the corresponding costs, changes to mortality, and quality of life assigned. Direct costs are assessed from the perspective of a comprehensive US healthcare payer ($US, 2012 values). Quit attempt strategies that can be evaluated in the current simulation include unassisted quit attempts, brief counselling, behavioural modification therapy, nicotine replacement therapy, bupropion, and varenicline, with the selection of strategies and time between quit attempts based on equations derived from survey data. Equations predicting the success of quit attempts as well as the short-term probability of relapse were derived from five varenicline clinical trials.

Results

Concordance between the five trials and predictions from the simulation on abstinence at 12 months was high, indicating that the equations predicting success and relapse in the first year following a quit attempt were reliable. Predictions allowing for only a single quit attempt versus unrestricted attempts demonstrate important differences, with the single quit attempt simulation predicting 19 % more smoking-related diseases and 10 % higher costs associated with smoking-related diseases. Differences are most prominent in predictions of the time that individuals abstain from smoking: 13.2 years on average over a lifetime allowing for multiple quit attempts, versus only 1.2 years with single quit attempts. Differences in abstinence time estimates become substantial only 5 years into the simulation. In the multiple quit attempt simulations, younger individuals survived longer, yet had lower lifetime smoking-related disease and total costs, while the opposite was true for those with high levels of nicotine dependence.

Conclusion

By allowing for multiple quit attempts over the course of individuals’ lives, the simulation can provide more reliable estimates on the health and economic impact of interventions designed to increase abstinence from smoking. Furthermore, the individual nature of the simulation allows for evaluation of outcomes in populations with different baseline profiles. DES provides a framework for comprehensive and appropriate predictions when applied to smoking cessation over smoker lifetimes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Centers for Disease Control and Prevention (CDC). Annual smoking-attributable mortality, years of potential life lost, and economic costs—United States, 1995–1999. MMWR Morb Mortal Wkly Rep. 2002;14:300–3. Centers for Disease Control and Prevention (CDC). Annual smoking-attributable mortality, years of potential life lost, and economic costs—United States, 1995–1999. MMWR Morb Mortal Wkly Rep. 2002;14:300–3.
2.
Zurück zum Zitat Centers for Disease Control and Prevention (CDC). State-specific smoking-attributable mortality and years of potential life lost—United States, 2000–2004. MMWR Morb Mortal Wkly Rep. 2009;58(2):29–33. Centers for Disease Control and Prevention (CDC). State-specific smoking-attributable mortality and years of potential life lost—United States, 2000–2004. MMWR Morb Mortal Wkly Rep. 2009;58(2):29–33.
3.
Zurück zum Zitat Agaku I, King B, Dube SR. Current cigarette smoking among adults – United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(44):889–94. Agaku I, King B, Dube SR. Current cigarette smoking among adults – United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(44):889–94.
4.
Zurück zum Zitat Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99(1):29–38.PubMedCrossRef Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99(1):29–38.PubMedCrossRef
5.
Zurück zum Zitat Hyland A, Borland R, Li Q, et al. Individual-level predictors of cessation behaviours among participants in the International Tobacco Control (ITC) Four Country Survey. Tob Control. 2006;15 Suppl. 3:iii83–94.PubMedCrossRef Hyland A, Borland R, Li Q, et al. Individual-level predictors of cessation behaviours among participants in the International Tobacco Control (ITC) Four Country Survey. Tob Control. 2006;15 Suppl. 3:iii83–94.PubMedCrossRef
6.
Zurück zum Zitat Hymowitz N, Cummings KM, Hyland A, et al. Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tob Control. 1997;6(Suppl. 2):S57–62.PubMedCrossRef Hymowitz N, Cummings KM, Hyland A, et al. Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tob Control. 1997;6(Suppl. 2):S57–62.PubMedCrossRef
7.
Zurück zum Zitat Fiore M, Jaen C, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville: US Department of Health and Human Services, US Public Health Service; 2008 Fiore M, Jaen C, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville: US Department of Health and Human Services, US Public Health Service; 2008
8.
Zurück zum Zitat Fix BV, Hyland A, Rivard C, et al. Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006–2008 International Tobacco Control (ITC) Four Country Survey. Int J Environ Res Public Health. 2011;8(1):222–33.PubMedCrossRef Fix BV, Hyland A, Rivard C, et al. Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006–2008 International Tobacco Control (ITC) Four Country Survey. Int J Environ Res Public Health. 2011;8(1):222–33.PubMedCrossRef
9.
Zurück zum Zitat Chantix U.S. Consumer Attitudes, Trends, and Usage Research—Wave 8 Report—April 2010; conducted by Opinion Research Corporation Guideline, Inc., Princeton NJ and Pfizer, Inc. New York (data on file) Chantix U.S. Consumer Attitudes, Trends, and Usage Research—Wave 8 Report—April 2010; conducted by Opinion Research Corporation Guideline, Inc., Princeton NJ and Pfizer, Inc. New York (data on file)
10.
Zurück zum Zitat Yeomans K, Payne KA, Marton JP, et al. Smoking, smoking cessation and smoking relapse patterns: a web-based survey of current and former smokers in the US. Int J Clin Pract. 2011;65(10):1043–54.PubMedCrossRef Yeomans K, Payne KA, Marton JP, et al. Smoking, smoking cessation and smoking relapse patterns: a web-based survey of current and former smokers in the US. Int J Clin Pract. 2011;65(10):1043–54.PubMedCrossRef
11.
Zurück zum Zitat Ferguson J, Bauld L, Chesterman J, et al. The English smoking treatment services: one-year outcomes. Addiction. 2005;100(Suppl. 2):59–69.PubMedCrossRef Ferguson J, Bauld L, Chesterman J, et al. The English smoking treatment services: one-year outcomes. Addiction. 2005;100(Suppl. 2):59–69.PubMedCrossRef
12.
Zurück zum Zitat Fiore M, Jaén C, Baker T, et al. Treating tobacco use and dependence: 2008 update. Quick reference guide for clinicians. Rockville: US Department of Health and Human Services, US Public Health Service; 2009 Fiore M, Jaén C, Baker T, et al. Treating tobacco use and dependence: 2008 update. Quick reference guide for clinicians. Rockville: US Department of Health and Human Services, US Public Health Service; 2009
13.
Zurück zum Zitat Bolin K. Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models. Pharmacoeconomics. 2012;30(7):551–64.PubMedCrossRef Bolin K. Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models. Pharmacoeconomics. 2012;30(7):551–64.PubMedCrossRef
14.
Zurück zum Zitat Olsen KR, Bilde L, Juhl HH, et al. Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database. Eur J Health Econ. 2006;7(4):255–64.PubMedCrossRef Olsen KR, Bilde L, Juhl HH, et al. Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database. Eur J Health Econ. 2006;7(4):255–64.PubMedCrossRef
15.
Zurück zum Zitat Levy DT, Friend K. A simulation model of policies directed at treating tobacco use and dependence. Med Decis Making. 2002;22(1):6–17.PubMed Levy DT, Friend K. A simulation model of policies directed at treating tobacco use and dependence. Med Decis Making. 2002;22(1):6–17.PubMed
16.
Zurück zum Zitat Xenakis JG, Kinter ET, Ishak KJ, et al. A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data. Pharmacoeconomics. 2011;29(6):497–510.PubMedCrossRef Xenakis JG, Kinter ET, Ishak KJ, et al. A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data. Pharmacoeconomics. 2011;29(6):497–510.PubMedCrossRef
17.
Zurück zum Zitat Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47–55.PubMedCrossRef Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47–55.PubMedCrossRef
18.
Zurück zum Zitat Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56–63.PubMedCrossRef Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56–63.PubMedCrossRef
19.
Zurück zum Zitat Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63(8):717–24.PubMedCrossRef Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63(8):717–24.PubMedCrossRef
20.
Zurück zum Zitat Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121(2):221–9.PubMedCrossRef Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121(2):221–9.PubMedCrossRef
21.
Zurück zum Zitat Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest. 2011;139(3):591–9.PubMedCrossRef Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest. 2011;139(3):591–9.PubMedCrossRef
22.
Zurück zum Zitat Thun MJ. Data from Cancer Prevention Study II, 1982–1988 [provided by author – Michael J. Thun] Thun MJ. Data from Cancer Prevention Study II, 1982–1988 [provided by author – Michael J. Thun]
25.
27.
Zurück zum Zitat Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2005;(2):CD001292 Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2005;(2):CD001292
28.
Zurück zum Zitat Wetter DW, Kenford SL, Welsch SK, et al. Prevalence and predictors of transitions in smoking behavior among college students. Health Psychol. 2004;23(2):168–77.PubMedCrossRef Wetter DW, Kenford SL, Welsch SK, et al. Prevalence and predictors of transitions in smoking behavior among college students. Health Psychol. 2004;23(2):168–77.PubMedCrossRef
29.
Zurück zum Zitat Hoogenveen RT, van Baal PH, Boshuizen HC, et al. Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: the role of time since cessation. Cost Eff Resour Alloc. 2008;6:1.PubMedCrossRef Hoogenveen RT, van Baal PH, Boshuizen HC, et al. Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: the role of time since cessation. Cost Eff Resour Alloc. 2008;6:1.PubMedCrossRef
31.
Zurück zum Zitat Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–215.PubMedCrossRef Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–215.PubMedCrossRef
32.
Zurück zum Zitat Williams GR, Jiang JG, Matchar DB, et al. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke. 1999;30(12):2523–8.PubMedCrossRef Williams GR, Jiang JG, Matchar DB, et al. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke. 1999;30(12):2523–8.PubMedCrossRef
35.
Zurück zum Zitat Bronnum-Hansen H, Jorgensen T, Davidsen M, et al. Survival and cause of death after myocardial infarction: the Danish MONICA study. J Clin Epidemiol. 2001;54(12):1244–50.PubMedCrossRef Bronnum-Hansen H, Jorgensen T, Davidsen M, et al. Survival and cause of death after myocardial infarction: the Danish MONICA study. J Clin Epidemiol. 2001;54(12):1244–50.PubMedCrossRef
36.
Zurück zum Zitat de Torres JP, Cote CG, Lopez MV, et al. Sex differences in mortality in patients with COPD. Eur Respir J. 2009;33(3):528–35.PubMedCrossRef de Torres JP, Cote CG, Lopez MV, et al. Sex differences in mortality in patients with COPD. Eur Respir J. 2009;33(3):528–35.PubMedCrossRef
37.
Zurück zum Zitat Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest. 2004;125(1):27–37.PubMedCrossRef Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest. 2004;125(1):27–37.PubMedCrossRef
38.
Zurück zum Zitat Wolfe CD, Smeeton NC, Coshall C, et al. Survival differences after stroke in a multiethnic population: follow-up study with the South London stroke register. BMJ. 2005;331(7514):431.PubMedCrossRef Wolfe CD, Smeeton NC, Coshall C, et al. Survival differences after stroke in a multiethnic population: follow-up study with the South London stroke register. BMJ. 2005;331(7514):431.PubMedCrossRef
39.
Zurück zum Zitat Sullivan PW, Ghushchyan V. Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Med Decis Making. 2006;26(4):401–9.PubMedCrossRef Sullivan PW, Ghushchyan V. Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Med Decis Making. 2006;26(4):401–9.PubMedCrossRef
40.
Zurück zum Zitat Howard P, Knight C, Boler A, et al. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics. 2008;26(6):497–511.PubMedCrossRef Howard P, Knight C, Boler A, et al. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics. 2008;26(6):497–511.PubMedCrossRef
41.
Zurück zum Zitat Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58(5):388–93.PubMedCrossRef Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58(5):388–93.PubMedCrossRef
42.
Zurück zum Zitat Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619–37.PubMedCrossRef Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619–37.PubMedCrossRef
43.
Zurück zum Zitat Trippoli S, Vaiani M, Lucioni C, et al. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics. 2001;19(8):855–63.PubMedCrossRef Trippoli S, Vaiani M, Lucioni C, et al. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics. 2001;19(8):855–63.PubMedCrossRef
44.
Zurück zum Zitat Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89–102.PubMedCrossRef Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89–102.PubMedCrossRef
45.
Zurück zum Zitat Hay JW, Sterling KL. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Pharmacoeconomics. 2005;23(2):133–41.PubMedCrossRef Hay JW, Sterling KL. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Pharmacoeconomics. 2005;23(2):133–41.PubMedCrossRef
46.
Zurück zum Zitat Duncan PW, Lai SM, Keighley J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology. 2000;39(5):835–41.PubMedCrossRef Duncan PW, Lai SM, Keighley J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology. 2000;39(5):835–41.PubMedCrossRef
47.
Zurück zum Zitat Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003;21(3):191–200.PubMedCrossRef Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003;21(3):191–200.PubMedCrossRef
49.
Zurück zum Zitat O’Sullivan AK, Rubin J, Nyambose J, et al. Cost estimation of cardiovascular disease events in the US. Pharmacoeconomics. 2011;29(8):693–704.PubMedCrossRef O’Sullivan AK, Rubin J, Nyambose J, et al. Cost estimation of cardiovascular disease events in the US. Pharmacoeconomics. 2011;29(8):693–704.PubMedCrossRef
50.
Zurück zum Zitat Dalal AA, Christensen L, Liu F, et al. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis. 2010;5:341–9.PubMedCrossRef Dalal AA, Christensen L, Liu F, et al. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis. 2010;5:341–9.PubMedCrossRef
51.
Zurück zum Zitat Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28.PubMedCrossRef Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28.PubMedCrossRef
52.
Zurück zum Zitat MAG Mutual Healthcare Solutions. Physicians’ Fee and Coding Guide: 2012. MAG Mutual Healthcare Solutions Incorporated; 2012. MAG Mutual Healthcare Solutions. Physicians’ Fee and Coding Guide: 2012. MAG Mutual Healthcare Solutions Incorporated; 2012.
Metadaten
Titel
Smoking Cessation Treatment and Outcomes Patterns Simulation: A New Framework for Evaluating the Potential Health and Economic Impact of Smoking Cessation Interventions
verfasst von
Denis Getsios
Jenő P. Marton
Nikhil Revankar
Alexandra J. Ward
Richard J. Willke
Dale Rublee
K. Jack Ishak
James G. Xenakis
Publikationsdatum
01.09.2013
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 9/2013
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-013-0070-5

Weitere Artikel der Ausgabe 9/2013

PharmacoEconomics 9/2013 Zur Ausgabe